A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo

Laboratory research and pharmacoepidemiology provide support for metformin as a potential antitumor agent. However, the lack of a clear understanding of the indications of metformin limits its efficacy. Here, we performed a genome-wide CRISPR knockout negative screen to identify potential targets th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yarui, Zhu, Qing, Liang, Junbo, Li, Yifei, Li, Mo, Zhang, Ying, Wang, Xiaobing, Zeng, Yixin, Jiao, Yuchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434905/
https://www.ncbi.nlm.nih.gov/pubmed/32811807
http://dx.doi.org/10.1038/s41392-020-0203-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434905/
https://www.ncbi.nlm.nih.gov/pubmed/32811807
http://dx.doi.org/10.1038/s41392-020-0203-1

Ejemplares similares